Factors influencing the production of recombinant SV40 vectors

被引:12
|
作者
Vera, M
Prieto, J
Strayer, DS
Fortes, P
机构
[1] Univ Navarra, Sch Med, Fdn Appl Med Res, Div Gene Therapy,Lab Vector Dev, Pamplona 31008, Spain
[2] Jefferson Med Coll, Dept Pathol & Cell Biol, Philadelphia, PA 19107 USA
关键词
SV40; recombinant SV40 vectors; gene therapy; production; titration; DI particles; wtSV40; revertants;
D O I
10.1016/j.ymthe.2004.06.1014
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Most gene therapy approaches employ viral vectors for gene delivery. Ideally, these vectors should be produced at high titer and purity with well-established protocols. Standardized methods to measure the quality of the vectors produced are imperative, as are techniques that allow reproducible quantitation of viral titer. We devised a series of protocols that achieve high-titer production and reproducible purification and provide for quality control and titering of recombinant simian virus 40 vectors (rSV40s). rSV40s are good candidate vehicles for gene transfer: they are easily modified to be nonreplicative and they are nonimmunogenic. Further, they infect a wide variety of cells and allow long-term transgene expression. We report here these protocols to produce rSV40 vectors in high yields, describe their purification, and characterize viral stocks using quality control techniques that monitor the presence of wild-type SV40 revertants and defective interfering particles. Several methods for reproducible titration of rSV40 viruses have been compared. We believe that these techniques can be widely applied to obtain high concentrations of high-quality rSV40 viruses reproducibly.
引用
收藏
页码:780 / 791
页数:12
相关论文
共 50 条
  • [21] PARTIAL IMMUNITY OF SV40 CRYPTIC TRANSFORMANTS TO RETRANSFORMATION BY SV40
    REIN, A
    SMITH, HS
    IN VITRO-JOURNAL OF THE TISSUE CULTURE ASSOCIATION, 1972, 7 (04): : 256 - &
  • [22] Conditional expression of α1-antitrypsin delivered by recombinant SV40 vectors protects lymphocytes against HIV
    Cordelier, P
    Strayer, DS
    GENE THERAPY, 2003, 10 (26) : 2153 - 2156
  • [23] STRUCTURE OF ACTIVE CHROMATIN AS STUDIED IN SV40 AND RECOMBINANT MINICHROMOSOMES
    DEBERNARDIN, W
    KOLLER, T
    BEARD, P
    SOGO, JM
    EXPERIENTIA, 1987, 43 (06): : 682 - 682
  • [24] SV40 pseudovirions are efficient and safe myocardial gene therapy vectors
    Beeri, R
    Pugatsch, T
    Abedat, S
    Latif, MA
    Oppenheim, A
    MOLECULAR THERAPY, 2004, 9 : S356 - S357
  • [25] MAMMALIAN-CELL TRANSFORMATION WITH SV40 HYBRID PLASMID VECTORS
    SOUTHERN, PJ
    IN VITRO-JOURNAL OF THE TISSUE CULTURE ASSOCIATION, 1982, 18 (03): : 315 - 315
  • [26] A packaging system for SV40 vectors without vital coding sequences
    Sect. of Thoracic Molecular Oncology, Dept. of Thorac. and Cardiovasc. S., Univ. of Texas M. D. Anderson C., Houston, TX 77030, United States
    不详
    不详
    ANAL. BIOCHEM., 1 (139-143):
  • [27] A packaging system for SV40 vectors without viral coding sequences
    Fang, BL
    Koch, P
    Bouvet, M
    Ji, L
    Roth, JA
    ANALYTICAL BIOCHEMISTRY, 1997, 254 (01) : 139 - 143
  • [28] In vitro constructed SV40 pseudovirions: Vectors for hematopoietic tissue.
    Kimchi-Sarfaty, C
    Ben-nun-Shaul, O
    Goldenberg, D
    Rund, DG
    Gottesman, MM
    Oppenheim, A
    BLOOD, 2000, 96 (11) : 432A - 432A
  • [29] INTEGRATION OF SV40
    PRASAD, I
    BASILICO, C
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1975, 16 (MAR): : 20 - 20
  • [30] SV40 DEFECTIVENESS
    不详
    NATURE, 1973, 245 (5426) : 409 - 410